Oklahoma 2025 Regular Session

Oklahoma House Bill HB2047 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	SENATE FLOOR VERSION - HB2047 SFLR Page 1
4		-	(Bold face denotes Committee Amendments) 1
	3	+	ENGR. H. B. NO. 2047 Page 1 1
5	4		2
6	5		3
7	6		4
8	7		5
9	8		6
10	9		7
11	10		8
12	11		9
13	12		10
14	13		11
15	14		12
16	15		13
17	16		14
18	17		15
19	18		16
20	19		17
21	20		18
22	21		19
23	22		20
24	23		21
25	24		22
26	25		23
27	26		24
28	27
29		-	SENATE FLOOR VERSION
30		-	April 15, 2025
31		-
32		-
33	28		ENGROSSED HOUSE
34		-	BILL NO. 2047 By: Stinson, Archer~~, Roe,~~ and
35		-	~~Miller of~~ the House
	29	+	BILL NO. 2047 By: Stinson, Archer and Roe of
	30	+	the House
36	31
37	32		and
38	33
39	34		Hines of the Senate
40	35
41	36
42	37
43	38
44	39
45	40		An Act relating to schools; creating the Emerson Kate
46	41		Cole Act; amending 70 O.S. 2021, Section 1 -116.3,
47	42		which relates to school medication policies;
48	43		eliminating references to epinephrine injectors;
49	44		eliminating reference to certain training program;
50	45		modifying certain policy provisions regarding parent
51	46		permissions; requiring school to call 911 if
52	47		Epinephrine is administered to a student; mandating
53	48		school to notify parent if student experiences
54	49		possible allergic reaction; requiring school
55	50		districts to use mode l policies; requiring annual
56	51		training for certain teachers and school employees;
57	52		prescribing content and method for training; and
58	53		providing for noncodification.
59	54
60	55
61	56
62	57
63	58		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
64	59		SECTION 1. NEW LAW A new section of law not to be
65	60		codified in the Oklahoma Statutes reads as follows:
66	61		This act shall be known and may be cited as the "Emerson Kate
67	62		Cole Act".
68	63		SECTION 2. AMENDATORY 70 O.S. 2021, Section 1 -116.3, is
69	64		amended to read as follows:
	65	+	Section 1-116.3. A. Notwithstanding the provisions of Section
	66	+	1-116.2 of this title, the board of education of each school
70	67
71		-	SENATE FLOOR VERSION - HB2047 SFLR Page 2
72		-	(Bold face denotes Committee Amendments) 1
	68	+	ENGR. H. B. NO. 2047 Page 2 1
73	69		2
74	70		3
75	71		4
76	72		5
77	73		6
78	74		7
79	75		8
80	76		9
81	77		10
82	78		11
83	79		12
84	80		13
85	81		14
86	82		15
87	83		16
88	84		17
89	85		18
90	86		19
91	87		20
92	88		21
93	89		22
94	90		23
95	91		24
96	92
97		-	Section 1-116.3. A. Notwithstanding the provisions of Section
98		-	1-116.2 of this title, the board of education of each school
99	93		district shall adopt a policy on or before September 1, 2008, that
100	94		permits the self-administration of inhaled asthma medication by a
101	95		student for treatment of asthma, the self -administration of
102	96		anaphylaxis medication by a student for treatment of anaphylaxis and
103	97		the self-administration of replacement pancreatic enzymes by a
104	98		student for treatment of cystic fibrosis. The policy shall require:
105	99		1. The parent or guardian of the student to authorize in
106	100		writing the student's self-administration of medication;
107	101		2. The parent or guardian of the student to provide to the
108	102		school a written statement from the physician treating the student
109	103		that the student has asthma, anaphylaxis or cystic fibrosis and is
110	104		capable of, and has been instructed in the proper method of, self -
111	105		administration of medication;
112	106		3. The parent or guardian of the student to provide to the
113	107		school an emergency supply of the student 's medication to be
114	108		administered pursuant to the provisions of Section 1 -116.2 of this
115	109		title;
116	110		4. The school district to inform the parent or guardian of the
117	111		student, in writing, that the school district and its employees and
118	112		agents shall incur no liability as a result of any injury arising
119	113		from the self-administration of medication by the student; and
	114	+	5. The parent or guardian of th e student to sign a statement
	115	+	acknowledging that the school district shall incur no liability as a
120	116
121		-	SENATE FLOOR VERSION - HB2047 SFLR Page 3
122		-	(Bold face denotes Committee Amendments) 1
	117	+	ENGR. H. B. NO. 2047 Page 3 1
123	118		2
124	119		3
125	120		4
126	121		5
127	122		6
128	123		7
129	124		8
130	125		9
131	126		10
132	127		11
133	128		12
134	129		13
135	130		14
136	131		15
137	132		16
138	133		17
139	134		18
140	135		19
141	136		20
142	137		21
143	138		22
144	139		23
145	140		24
146	141
147		-	5. The parent or guardian of the student to sign a statement
148		-	acknowledging that the school district shall incur no liability as a
149	142		result of any injury arising from the self -administration of
150	143		medication by the student.
151	144		B. The school board of each school district that elects to
152	145		stock Epinephrine injectors or inhalers shall amend the policy
153	146		identified in subsection A of this section.
154	147		1. The amended policy for Epinephrine injectors shall require:
155	148		a. the school district to inform the parent or guardian
156	149		of each student, in writing, that a sc hool nurse or
157	150		school employee trained by a health care professional
158	151		or trained in correlation with the State Department of
159	152		Health's Diabetes Management Annual School Training
160	153		Program pursuant to subsection G of this section may
161	154		administer, with parent or guardian permission but
162	155		without a health care provider order, an Epinephrine
163	156		injection to a student whom the school nurse or
164	157		trained school employee in good faith believes is
165	158		having an anaphylactic reaction,
166	159		b. a waiver of liability executed by a parent or guardian
167	160		be on file with the school district prior to the
168	161		administration of an Epinephrine injection pursuant to
169	162		paragraph 1 of this subsection, and
	163	+	c. the school district to designate the employee
	164	+	responsible for obtaining the Epinephrine injectors at
	165	+	each school site.
170	166
171		-	SENATE FLOOR VERSION - HB2047 SFLR Page 4
172		-	(Bold face denotes Committee Amendments) 1
	167	+	ENGR. H. B. NO. 2047 Page 4 1
173	168		2
174	169		3
175	170		4
176	171		5
177	172		6
178	173		7
179	174		8
180	175		9
181	176		10
182	177		11
183	178		12
184	179		13
185	180		14
186	181		15
187	182		16
188	183		17
189	184		18
190	185		19
191	186		20
192	187		21
193	188		22
194	189		23
195	190		24
196	191
197		-	c. the school district to designate the employee
198		-	responsible for obtaining the Epinephrine injectors at
199		-	each school site.
200	192		2. The amended policy for inhalers shall require:
201	193		a. the school district to inform the parent or guardian
202	194		of each student, in writing, that a school nurse or
203	195		school employee trained by a health care professional
204	196		may administer an inhaler to a student whom the school
205	197		nurse or trained school employee in good faith
206	198		believes is having respiratory distress,
207	199		b. the school district to designate the employee
208	200		responsible for obtaining the inhalers and spacers or
209	201		holding chambers at each school site, and
210	202		c. the school district to notify the parent or guardian
211	203		of a student after administration of an inhaler.
212	204		C. The school district and its employees and agents shall incur
213	205		no liability as a result of any injury arising pursuant to the
214	206		discharge or nondischarge of the powers provided for pursuant to
215	207		subparagraph a of paragraphs 1 and 2 of subsection B of this
216	208		section.
217	209		D. A licensed physician who has prescriptive authority may
218	210		write a prescription for Epinephrine injectors and inhalers and
219	211		spacers or holding chambers to the school district in the name of
220	212		the district as a body corporate specified in Section 5 -105 of this
	213	+	title which shall be maintained at each school site. Such physician
	214	+	shall incur no liability as a result of any injury arising from the
221	215
222		-	SENATE FLOOR VERSION - HB2047 SFLR Page 5
223		-	(Bold face denotes Committee Amendments) 1
	216	+	ENGR. H. B. NO. 2047 Page 5 1
224	217		2
225	218		3
226	219		4
227	220		5
228	221		6
229	222		7
230	223		8
231	224		9
232	225		10
233	226		11
234	227		12
235	228		13
236	229		14
237	230		15
238	231		16
239	232		17
240	233		18
241	234		19
242	235		20
243	236		21
244	237		22
245	238		23
246	239		24
247	240
248		-	title which shall be maintained at each school site. Such physician
249		-	shall incur no liabilit y as a result of any injury arising from the
250	241		use of the Epinephrine injectors or the inhalers and spacers or
251	242		holding chambers.
252	243		E. The school district may maintain at each school a minimum of
253	244		two Epinephrine injectors devices and two inhalers with spacers or
254	245		holding chambers in a secure location. Pro vided, however, that
255	246		nothing in this section shall be construed as creating or imposing a
256	247		duty on a school district to maintain Epinephrine injectors or
257	248		inhalers with spacers or holding chambers at a school site or sites.
258	249		F. In the event a student is beli eved to be having an
259	250		anaphylactic reaction or respiratory distress, a school employee
260	251		shall contact 911 as soon as possible. If Epinephrine is
261	252		administered to a student, a school employee shall contact 911 as
262	253		soon as possible. The school district shall n otify the parent or
263	254		guardian of any student who experiences a possible allergic reaction
264	255		as soon as possible.
265	256		G. The State Board of Education, in consultation with the State
266	257		Board of Health, shall develop model policies which school districts
267	258		may shall use in compliance with this section. The model policies
268	259		shall include, at a minimum, required annual training for teachers
269	260		and school employees who are directly responsible for students on
270	261		the topics of food allergies, recognizing anaphylaxis, and
271	262		instruction on how to administer Epinephrine. The training shall be
	263	+	completed before the school year begins or upon hiring the teacher
	264	+	or school employee. Documentation certifying completion of the
272	265
273		-	SENATE FLOOR VERSION - HB2047 SFLR Page 6
274		-	(Bold face denotes Committee Amendments) 1
	266	+	ENGR. H. B. NO. 2047 Page 6 1
275	267		2
276	268		3
277	269		4
278	270		5
279	271		6
280	272		7
281	273		8
282	274		9
283	275		10
284	276		11
285	277		12
286	278		13
287	279		14
288	280		15
289	281		16
290	282		17
291	283		18
292	284		19
293	285		20
294	286		21
295	287		22
296	288		23
297	289		24
298	290
299		-	completed before the school year begins or upon hiring the teacher
300		-	or school employee. Documentation certifying completion of the
301	291		required training shall be retained in the personnel file of the
302	292		teacher or school employee. The training may be provided online or
303	293		in person by the school nurse or a recognized food allergy and
304	294		anaphylaxis training program.
305	295		H. The State Board of Education, in consultation with the State
306	296		Board of Health, shall promulg ate rules to implement this section.
307	297		I. As used in this section:
308	298		1. "Medication" means a metered dose inhaler or a dry powder
309	299		inhaler to alleviate asthmatic symptoms, prescribed by a physician
310	300		and having an individual label, an anaphylaxis medication use d to
311	301		treat anaphylaxis including but not limited to Epinephrine injectors
312	302		prescribed by a physician and having an individual label, or
313	303		replacement pancreatic enzymes prescribed by a physician and having
314	304		an individual label; and
315	305		2. "Self-administration" means a student's use of medication
316	306		pursuant to prescription or written direction from a physician .;
317	307		3. "Respiratory distress " means the perceived or actual
318	308		presence of coughing, wheezing or shortness of breath; and
319	309		4. "Inhaler" means a device that deliver s a bronchodilator to
320	310		alleviate symptoms of respiratory distress that is manufactured in
321	311		the form of a metered -dose inhaler or dry-powder inhaler and that
	312	+	may include a spacer or holding chamber that attaches to the inhaler
	313	+	to improve the delivery of the b ronchodilator.
322	314
323		-	SENATE FLOOR VERSION - HB2047 SFLR Page 7
324		-	(Bold face denotes Committee Amendments) 1
	315	+	ENGR. H. B. NO. 2047 Page 7 1
325	316		2
326	317		3
327	318		4
328	319		5
329	320		6
330	321		7
331	322		8
332	323		9
333	324		10
334	325		11
335	326		12
336	327		13
337	328		14
338	329		15
339	330		16
340	331		17
341	332		18
342	333		19
343	334		20
344	335		21
345	336		22
346	337		23
347	338		24
348	339
349		-	may include a spacer or holding chamber that attaches t o the inhaler
350		-	to improve the delivery of the bronchodilato r.
351	340		J. The permission for self -administration of asthma,
352	341		anaphylaxis or replacement pancreatic enzyme medication is effective
353	342		for the school year for which it is granted and shall be renewed
354	343		each subsequent school year upon fulfillment of the r equirements of
355	344		this section.
356	345		K. A student who is permitted to self -administer asthma,
357	346		anaphylaxis or replacement pancreatic enzyme medication pursuant to
358	347		this section shall be permitted to possess and use a prescribed
359	348		inhaler, anaphylaxis medication inclu ding but not limited to an
360	349		Epinephrine injector, or replacement pancreatic enzyme medication at
361	350		all times.
362		-	COMMITTEE REPORT BY: COMMITTEE ON EDUCATION
363		-	April 15, 2025 - DO PASS
	351	+	Passed the House of Representatives the 26th day of March, 2025.
	352	+
	353	+
	354	+
	355	+
	356	+	Presiding Officer of the House
	357	+	of Representatives
	358	+
	359	+
	360	+
	361	+	Passed the Senate the _____ day of __________, 2025.
	362	+
	363	+
	364	+
	365	+
	366	+	Presiding Officer of the Senate